Literature DB >> 2941257

The comparative in vitro activity of twelve 4-quinolone antimicrobials against enteric pathogens.

M D O'Hare, D Felmingham, G L Ridgway, R N Grüneberg.   

Abstract

The minimal inhibitory concentrations (MICs) of twelve 4-quinolone antimicrobials were determined for Salmonella typhi (25), Salmonella spp. (50), Shigella spp. (50), Campylobacter jejuni (100), Vibrio cholerae (10), Vibrio parahaemolyticus (10), Yersinia enterocolitica (25), Aeromonas hydrophila (25) and Plesiomonas shigelloides (10). MICs were determined using an agar dilution technique in Mueller-Hinton agar (Oxoid, England) supplemented with 10% lysed horse blood. Antibiotic containing plates were inoculated with approximately 10(4) colony forming units of each organism, contained in 10 microliters of Mueller-Hinton broth (Oxoid, England), using a multipoint inoculator. Following inoculation plates were incubated aerobically for 18 hours at 37 degrees C, except for plates inoculated with Campylobacter jejuni which were incubated microaerophilically for 48 hours at 37 degrees C. The MICs of each antimicrobial for each isolate examined, together with the minimum concentrations of each antimicrobial required to inhibit 50% (MIC50) and 90% (MIC90) of the isolates examined, were also determined. The more recently synthesized 4-quinolones showed very good activity against all of the enteric pathogens examined with ciprofloxacin being the most active (MIC90: Salmonella typhi 0.015 microgram/ml, Salmonella spp. 0.015 microgram/ml, Shigella spp. 0.015 microgram/ml, Campylobacter jejuni 0.12 microgram/ml, Vibrio cholerae 0.008 microgram/ml, Vibrio parahaemolyticus 0.06 microgram/ml, Yersinia enterocolitica 0.015 microgram/ml, Aeromonas hydrophila 0.015 microgram/ml and Plesiomonas shigelloides 0.015 microgram/ml. Where considered clinically appropriate these compounds may have a useful role in the treatment and prevention of diarrhoeal disease caused by these enteric pathogens.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2941257

Source DB:  PubMed          Journal:  Drugs Exp Clin Res        ISSN: 0378-6501


  12 in total

1.  Endocarditis due to Yersinia enterocolitica.

Authors:  E Bonnet; M Archambaud; A Sommabere; C Suc; Z Elias; M Gallinier; P Massabuau; J P Bounhoure; P Massip
Journal:  Infection       Date:  1998 Sep-Oct       Impact factor: 3.553

2.  Comparison of single-dose treatment with norfloxacin and standard 5-day treatment with trimethoprim-sulfamethoxazole for acute shigellosis in adults.

Authors:  E Gotuzzo; R A Oberhelman; C Maguiña; S J Berry; A Yi; M Guzman; R Ruiz; R Leon-Barua; R B Sack
Journal:  Antimicrob Agents Chemother       Date:  1989-07       Impact factor: 5.191

3.  Characterization of the role of the ToxR-modulated outer membrane porins OmpU and OmpT in Vibrio cholerae virulence.

Authors:  D Provenzano; C M Lauriano; K E Klose
Journal:  J Bacteriol       Date:  2001-06       Impact factor: 3.490

4.  Epidemiological, clinical and therapeutic evaluation of the Italian cholera epidemic in 1994.

Authors:  P Maggi; S Carbonara; C Fico; T Santantonio; C Romanelli; E Sforza; G Pastore
Journal:  Eur J Epidemiol       Date:  1997-01       Impact factor: 8.082

Review 5.  Impact of the fluoroquinolones on gastrointestinal flora.

Authors:  V Korten; B E Murray
Journal:  Drugs       Date:  1993       Impact factor: 9.546

Review 6.  Quinolones in the treatment of acute bacterial diarrhoeal diseases.

Authors:  H E Akalin
Journal:  Drugs       Date:  1993       Impact factor: 9.546

Review 7.  The new quinolones in the treatment of diarrhoea and typhoid fever.

Authors:  A Waiz
Journal:  Drugs       Date:  1995       Impact factor: 9.546

Review 8.  Use of quinolones in the treatment of gastrointestinal infections.

Authors:  H L DuPont
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

Review 9.  Ofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  J P Monk; D M Campoli-Richards
Journal:  Drugs       Date:  1987-04       Impact factor: 9.546

Review 10.  Quinolones and the gastrointestinal tract.

Authors:  B E Murray
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-12       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.